United Therapeutics Stock Forecast, Price & News

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

Is United Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" United Therapeutics stock.
View analyst ratings for United Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than United Therapeutics?

Wall Street analysts have given United Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but United Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting United Therapeutics?

United Therapeutics saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 2,470,000 shares, a drop of 23.8% from the August 31st total of 3,240,000 shares. Based on an average daily trading volume, of 324,500 shares, the days-to-cover ratio is presently 7.6 days. Currently, 5.6% of the company's stock are short sold.
View United Therapeutics' Short Interest.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for United Therapeutics.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) issued its quarterly earnings results on Wednesday, August, 4th. The biotechnology company reported $3.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.02 by $0.63. The biotechnology company earned $446.50 million during the quarter, compared to analyst estimates of $378.54 million. United Therapeutics had a net margin of 29.60% and a trailing twelve-month return on equity of 13.69%. United Therapeutics's revenue was up 23.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.68 earnings per share.
View United Therapeutics' earnings history.

How has United Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

United Therapeutics' stock was trading at $93.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, UTHR shares have increased by 103.6% and is now trading at $191.34.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for UTHR?

8 Wall Street analysts have issued 1 year price targets for United Therapeutics' shares. Their forecasts range from $196.00 to $275.00. On average, they anticipate United Therapeutics' share price to reach $224.38 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price.
View analysts' price targets for United Therapeutics or view top-rated stocks among Wall Street analysts.

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the following people:

• Martine A. Rothblatt, Chairman & Chief Executive Officer
• Michael Ian Benkowitz, President & Chief Operating Officer
• James Christopher Edgemond, Chief Financial Officer & Treasurer
• Paul A. Mahon, Secretary, Executive VP & General Counsel
• Dewey Steadman, Head-Investor Relations

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics CEO Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among United Therapeutics' employees.

Who are some of United Therapeutics' key competitors?

Some companies that are related to United Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of UTHR's competitors.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), (CELG), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Robeco Institutional Asset Management B.V. (0.81%), Wedge Capital Management L L P NC (0.35%), Virginia Retirement Systems ET AL (0.27%), Frontier Capital Management Co. LLC (0.19%), New York State Teachers Retirement System (0.13%) and Assenagon Asset Management S.A. (0.10%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends for United Therapeutics.

Which institutional investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Wedge Capital Management L L P NC, Frontier Capital Management Co. LLC, Robeco Institutional Asset Management B.V., Virginia Retirement Systems ET AL, Greylin Investment Mangement Inc., Nisa Investment Advisors LLC, and State of Alaska Department of Revenue. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Christopher Patusky, Judy D Olian, Paul A Mahon, and Raymond Dwek.
View insider buying and selling activity for United Therapeutics or view top insider-selling stocks.

Which institutional investors are buying United Therapeutics stock?

UTHR stock was purchased by a variety of institutional investors in the last quarter, including Beck Bode LLC, Polianta Ltd, New England Research & Management Inc., Fifth Third Bancorp, Crossmark Global Holdings Inc., Joel Isaacson & Co. LLC, DekaBank Deutsche Girozentrale, and New York State Teachers Retirement System.
View insider buying and selling activity for United Therapeutics or or view top insider-buying stocks.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $191.34.

How much money does United Therapeutics make?

United Therapeutics has a market capitalization of $8.60 billion and generates $1.48 billion in revenue each year. The biotechnology company earns $514.80 million in net income (profit) each year or $11.54 on an earnings per share basis.

How many employees does United Therapeutics have?

United Therapeutics employs 950 workers across the globe.

When was United Therapeutics founded?

United Therapeutics was founded in 1996.

What is United Therapeutics' official website?

The official website for United Therapeutics is www.unither.com.

Where are United Therapeutics' headquarters?

United Therapeutics is headquartered at 1040 SPRING ST, SILVER SPRING MD, 20910.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at (301) 608-9292 or via email at [email protected].